Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brief therapy may offer Long-Term protection against relapse

NCT ID NCT07522775

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 806 Hong Kong adults who had received low-intensity cognitive behavioural therapy (LICBT) for common mental disorders like depression and anxiety. Researchers checked their mental health every 6 months for up to 4 years to see if improvements lasted. The goal was to understand how well this brief therapy prevents relapse over the long term.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-intensity cognitive behavioural therapy (LICBT)
What this could lead to
If successful, this could show that brief therapy helps people with common mental disorders stay well longer and avoid relapse.
What could go wrong
This is an observational follow-up, not a new treatment test. Results may not apply to all groups, and relapse rates could still be high.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

806 people

The number who actually took part.

Started

Oct 2021

Finished

Apr 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants were service users of a community mental health project in Hong Kong.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years old or above, * Capable of understanding Cantonese, * Received at least 2 sessions of LICBT since September 2017.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Common mental disorders (CMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • New Life Psychiatric Rehabilitation Association

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.